Performs clinical and specialty laboratory tests for physicians, hospitals, health plans and patients, and provides drug-development laboratory services for pharmaceutical, biotechnology and medical-device companies.
10-K for FY2025, filed Feb 24, 2026Labcorp® Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help…View ↗
Clients. Physicians and other healthcare providers who are authorized to order clinical laboratory testing for their patients are a primary…View ↗
The Company is organized under two segments: Dx, which includes routine testing and specialty/esoteric testing; and BLS, consisting of…View ↗
Dx offers a comprehensive menu of frequently requested core testing and specialty testing through an integrated network of primary and…View ↗
Diagnostic testing generates fees when testing is complete and results are reported; biopharma laboratory services are billed as work is delivered under fixed-price or fee-for-service contracts.
10-K for FY2025, filed Feb 24, 2026Within the Dx segment, a majority of the revenue transactions are initiated when Dx receives a requisition form to perform a diagnostic…View ↗
BLS revenue is generally recognized over time, as the services are delivered to the customer, based on the extent of progress towards…View ↗
Fixed-price contracts are typically recognized as revenue over time based on a proportional-performance basis, using either input or output…View ↗
Fee-for-service contracts are typically priced based on transaction volume or time and materials. For volume-based contracts, the contract…View ↗
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by reportable segment ↗$14B
10-K for FY2025, filed Feb 24, 2026
$14B ↗| Segment | Share | Revenue |
|---|---|---|
|
Diagnostics
|
78%
FY2022: 78%
|
Diagnostics, FY2025
$10.9B Sources
|
|
Biopharma Laboratory Services
|
22%
FY2022: 23%
|
Biopharma Laboratory Services, FY2025
$3.1B Sources
|
Physicians and other healthcare providers order diagnostic tests; health plans, government programs, clients and patients pay for them. Pharmaceutical, biotechnology and medical-device companies and CROs buy drug-development laboratory services through Labcorp's global sales organization.
10-K for FY2025, filed Feb 24, 2026Clients. Physicians and other healthcare providers who are authorized to order clinical laboratory testing for their patients are a primary…View ↗
Clinical laboratories submit bills for tests and other related services and are reimbursed by the applicable responsible party, which…View ↗
The BLS global sales and customer service organizations provide customer coverage primarily to pharmaceutical and biotechnology companies…View ↗
Yes. It kept 6 cents of every revenue dollar as net income in FY2025 and turned 9 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 30, 2026
$262.8MView ↗
10-Q for Q3 FY2026, filed Oct 30, 2026
Open tableView ↗
Flat. Revenue was $14B in FY2025, about the same as the $13.1B of FY2021.
Loading...